Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cost of Revenue: 2010-2024

Historic Cost of Revenue for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to $334,000.

  • Lineage Cell Therapeutics' Cost of Revenue fell 86.84% to $5,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $234,000, marking a year-over-year decrease of 46.33%. This contributed to the annual value of $334,000 for FY2024, which is 50.22% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Cost of Revenue of $334,000 as of FY2024, which was down 50.22% from $671,000 recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Cost of Revenue registered a high of $1.4 million during FY2021, and its lowest value of $334,000 during FY2024.
  • Its 3-year average for Cost of Revenue is $577,667, with a median of $671,000 in 2023.
  • In the last 5 years, Lineage Cell Therapeutics' Cost of Revenue skyrocketed by 270.39% in 2021 and then slumped by 50.22% in 2024.
  • Over the past 5 years, Lineage Cell Therapeutics' Cost of Revenue (Yearly) stood at $385,000 in 2020, then skyrocketed by 270.39% to $1.4 million in 2021, then crashed by 48.95% to $728,000 in 2022, then dropped by 7.83% to $671,000 in 2023, then plummeted by 50.22% to $334,000 in 2024.